Discussions will focus on how private space stations can improve access, repeatability and commercial feasibility for advanced biotech experiments
The upcoming multi-center, multinational Phase 1 study will evaluate safety, tolerability, pharmacokinetics, and early signs of efficacy
The 12-month alpha-testing phase will bring together ZEISS R&D, three academic collaborators, and three pharmaceutical industry partners
A major push to sharpen the future of cancer treatment is underway
The conference focuses on the latest advances in cancer diagnosis, treatment, and patient-centric care
The Stealth AXiS surgical navigation system was recently cleared by the US Food and Drug Administration (FDA) for cranial procedures in the United States
The new device promises faster, more efficient cardiac procedures while maintaining the safety and effectiveness clinicians expect
The new capital is expected to fund the company through 2029
India’s first prospective study finds molecular testing improved diagnostic clarity in 50% of complex sarcoma cases
SNV4818, the oral drug, is pan-mutant–selective PI3K? inhibitor aimed at treating HR+/HER2- breast cancer and potentially other solid tumors
Subscribe To Our Newsletter & Stay Updated
